Antithrombin-lowering in hemophilia: a closer look at fitusiran
Por um escritor misterioso
Descrição
Monthly injections of fitusiran found to reduce bleeds in patients with hemophilia A and B
Antithrombin-lowering in hemophilia: a closer look at fitusiran - ScienceDirect
Bleeding episodes significantly reduced in study of hemophilia drug
Fitusiran Prevents Bleeds in Hemophilia A or B Over Long Term, Study Finds
Fitusiran update following EAHAD 2021 Congress – WFH - World Federation of Hemophilia
RNAi targeting heparin cofactor II promotes hemostasis in hemophilia A: Molecular Therapy - Nucleic Acids
Thrombin generation for monitoring hemostatic therapy in hemophilia A: A narrative review - Verhagen - 2022 - Journal of Thrombosis and Haemostasis - Wiley Online Library
A Molecular Revolution in the Treatment of Hemophilia: Molecular Therapy
Efficacy and safety of fitusiran prophylaxis in people with haemophilia A or haemophilia B with inhibitors (ATLAS-INH): a multicentre, open-label, randomised phase 3 trial - The Lancet
Fitusiran Prophylaxis in Hemophilia With or Without Inhibitors
Non‐factor therapies for bleeding disorders: A primer for the general haematologist - Swan - 2022 - eJHaem - Wiley Online Library
A Molecular Revolution in the Treatment of Hemophilia. - Abstract - Europe PMC
Fitusiran prophylaxis 'great option' for reducing bleeds in people with hemophilia A or B
Single‐domain antibodies targeting antithrombin reduce bleeding in hemophilic mice with or without inhibitors
de
por adulto (o preço varia de acordo com o tamanho do grupo)
